Croda International Plc: management transactions · United Kingdom · RNS (LSE)

About Croda International Plc

Croda International Plc is a UK-based specialty chemicals group listed on the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom. The company positions itself around “smart science”: it develops high-performance ingredients and solutions used by industrial customers and consumer brands in formulations where functionality, quality and sustainability matter. Founded in 1925, Croda marked its centenary in 2025, highlighting a long operating history and a deep technical heritage. Its global headquarters are at Cowick Hall in Yorkshire, close to its original Rawcliffe Bridge site, which remains one of the company’s UK manufacturing locations. Croda’s business model is organised around three main divisions. Consumer Care serves markets closest to the end consumer, including beauty, personal care, home care and fragrance ingredients. Life Sciences covers pharmaceuticals, broader life sciences and agriculture, with solutions ranging from excipients and drug delivery systems to crop protection and seed enhancement technologies. Industrial Specialties addresses more technical markets such as coatings, water treatment, textiles, fibres and selected formulation-intensive industrial applications. This mix reduces reliance on any single end market while providing exposure to long-duration themes such as sustainable innovation, health, and formulation efficiency. From a competitive perspective, Croda stands out through its scientific specialization, application-led innovation and close customer relationships. That combination helps the group build strong positions in niche segments where technical requirements are high and switching costs can be meaningful. Croda emphasizes differentiated products and collaborative development with customers, particularly in markets where speed to market, performance, and regulatory compliance are critical. Geographically, Croda has a broad global footprint, operating across multiple countries with significant manufacturing, R&D and commercial activity in the UK, Europe, North America and Asia. The UK remains strategically important, hosting manufacturing, distribution, finance and specialist laboratory capabilities. Recent highlights include the opening in 2025 of a new lipids manufacturing facility in Pennsylvania to support its Pharma strategy, the release of 2025 full-year results showing improved momentum, and continued operational simplification and margin enhancement initiatives. The company also appointed a new CFO in 2025, underscoring an active phase of transformation at both operational and leadership levels.